Tirzepatide's ~5-day half-life1 is slightly shorter than semaglutide's, so levels decline a bit faster after a missed weekly dose — but still gradually, not abruptly. As always, what to *do* about a missed dose is for the product label and a clinician; here is only the pharmacology.

In plain terms: a slightly steeper slope than semaglutide, but still a slope, not a cliff.

The decline

From a ~5-day half-life1, using the standard half-life math2:

Days since last doseApprox. remaining of that dose
5~50%
7 (normal interval)~38%
10~25%
14~14%

Because the normal interval (7 days) already sits past one half-life, tirzepatide's weekly trough is naturally lower than semaglutide's — and a missed dose extends that decline further along the curve. Steady-state accumulation adds a buffer on top.

The point

The shape of the dip is set by the half-life. A shorter half-life means a steeper decline between doses and after a miss — the same reason tirzepatide's curve looks slightly "tighter" than semaglutide's. This is kinetics, not dosing guidance.

Modelling the dip from your own logged doses turns "did I miss one?" into a visible curve. Zyra Labs shows it — as information only, not medical advice.